Correlation between clinical trial endpoints of marketed cancer drugs and reimbursement decisions in China.

Objective: This study aimed to assess whether different clinical trial endpoints in pivotal trials of cancer drugs were associated with reimbursement decisions in China.

Materials And Methods: Cancer drugs marketed before June 30, 2021 with publicly available technical review reports for application of drug registration on Center for Drug Evaluation (CDE) website were reviewed. The trial design characteristics and relevant clinical outcomes [e.